Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (June 2014)
37 slides from Sorrento Therapeutics's investor presentation, Jun 3, 2014

Slide 1: Next-Generation Cancer Therapeutics
Exhibit 99.1 Exhibit Next-Generation 1June 2014 99.1 Cancer Therapeutics

Slide 2: Safe Harbor Statement
Safe This regarding or as Cynviloq™ presentation. information. 2Commission, all well Harbor presentation ofasthe our risks pending will Statement Assumptions The including business, inherent be contains Company amatters review NASDAQ: technologies its in and “forward-looking most funding, does and i

Slide 3: Management and Board of Directors
Management President, CEO Closed Amar Responsible Led George CCO startup David Co-inventor CTO Mike Regulatory and $430M Meritage Richard EVP Elan: values Board William Albany Teva Mark Watson, Cam Nerveda, Kim The Henry Sorrento Jaisim PDL Vuong Abraxis 3IgDraSol biologic Novacea oncology Scripps D

Slide 4: Next-Generation Cancer Therapeutics
Next-Generation High-diversity First-Patient-In Cynviloq ADC: G-MAB 4C-LockAntibody and targets K-Lock human Bioequivalence toxin Drug Cancer conjugation to Conjugate Abcancer Therapeutics librarycell Trial chemistries TUMOR Proprietary Bioequivalence Leadtoxins mAbregulatory programs and linkersinc

Slide 5: Pipeline
Multiple & Metastatic Non-Small Ovarian RTX INDICATION Oncology Oncology/Inflammation BI-SPECIFIC 5*ADC Partnership Intractable Cancer albumin-bound Commercialization >Breast Cell VEGFR2, PD-L1 AB Opportunities PRECLINICAL > (sNDA) Lung Cancer TARGET Cancer Oncology G-MAB Cancer c-Met, Pain paclitax

Slide 6: Lead Oncology Product Opportunity: Cynviloq
Lead Oncology Registration 6Cynviloq Trial Product Opportunity

Slide 7: Cynviloq: Maximum Tolerated Dose, Next Generation Paclitaxel
Cynviloq: Maximum ® 1st Polyoxyethylated Biological 260 2nd 73rd Cremophor Chemical Taxol Albumin mg/m2Cynviloq 175 Poly-lactide Mean paclitaxel *Analyst size :2polymer: Peak Next Est. polymer: bound- mg/m2 ELGeneration >=$1.7B* Generation castor projection; ~25andnm >300 Mean paclitaxel Conversion

Slide 8: Clinical Data Summary
Clinical Total Trials >300 Data Ongoing GPMBC301. Metastatic Completed Efficacy PM-Safety: Chemo-naïve 230 1st Phase 8260line mg/m2 suggestive number mg/m2 established 1:treatment 2: 2b 2 (IIS): Efficacy and trial (IIS): Breast trials for +safety (q3w) An of for Stage cis carbo MBC of patients in Op

Slide 9: Equivalent PK in Mice vs Abraxane
Equivalent Abraxane AUCinf 2.99 9Data 0.08 on file Vz61561.33 Cynviloq PK Cl IV Drug in bolus Mice 2103.71 HL at 30 (h)mg/kg; T487.32 max n(h) paclitaxel = 3(h*ng/mL) Cynviloq (mL/kg) 2.83 (mL/h/kg) 0.08 58151.31 Albumin 2103.58 bound-515.90

Slide 10: Comparable Human PK Data
Comparable Data Cmax (ng/ml) Albumin paclitaxel Cynviloq™ Abraxane 10 from AUCinf (ng/ml*h) bound- 1392 data 2 1357 separate PKfrom: Half-Life 5654 in5473 (hr) Humans Nuhad studies 12.9 (L 12.7 Cl /27.4 hrK. 25.5 (3/ m2) Ibrahim, h infusion, Phase 135 Img/m2 and Pharmacokinetic dose, n=3) Study of A

Slide 11: Bioequivalence - TRIBECA Trial
Bioequivalence -TRIBECA™ Key (n Albumin-bound Endpoints: Cmax First 11Patients Duration = 50) Parameters: patient (90% Infusion with =AUC CI) dosed 12 (TRIal MBC months =Duration: Dose: and time: Efficient March designed 260 30 (including 31, min 3mg/m2 Pathway weeks 2014 to evaluate patient Cycle +

Slide 12: Potential Cynviloq Advantages
Potential Albumin Cynviloq Maximum Paclitaxel >300 (mg/m2) Rapid no Convenient controlled No Cremophor-free Dosing *@ 12 higher foaming medium 260 reconstitution: q3w =higher Cynviloq bound- dose 175 MBC; temp Tolerated concerns storage for q3w* potential storage efficacy •Taxol ** •& Advantages Red

Slide 13: Next Steps: NDA Filing and Launch
NextStudy First BE NDA FDA LAUNCH 13 patient Approval Steps Filing 2014 2016 for 2015 dosed: Cynviloq 2016March 31, 2014 NDA filing: 2015 Product launch (MBC and NSCLC): 2016 sNDA planning for label expansion into LAUNCH pancreatic, bladder, and ovarian cancers

Slide 14: Clinical Stage Intractable Cancer Pain Management Asset
Clinical Stage Intractable RTX 14 Cancer PainPain Management Asset

Slide 15: Two Injection Sites, Two Products for Human Use
Two Injection Intraganglionic (injection 15 into Sites (injection Intrathecal = Twointo Products the or near for Human the ganglion) Use cerebrospinal fluid space)

Slide 16: RTX Ablates TRPV1-Positive Neurons
RTX limb Fore TRPV1 Adapted 16 Ablates TRPV1 positive from Hind TRPV1-positive Karai limb TRPV1 TRPV1 et al.negative 2004Neurons after Intrathecal Injection

Slide 17: Open-Label Study in Dogs with Osteosarcoma Pain
Open-Label Intractable Pain mm) to 100 (0 VAS Observational Lack No Animal Brown 60 17 Permanent (p 50 opioid-like osteosarcoma, Personality <of 40 et 0.0001 health serious 30 al,pain 20 Study 2005 analgesic Gait market for side 10 adverse due intact all 0in and not effects to 0Companion time repres

Slide 18: Effect of RTX Following Trigeminal Injection
Unilateral 120 140 160 Number 12 20 Left Adapted 18 345 blinks eye678 60 (blue) from Effect 100 40 Tender vs ofFollowing 80 Nociceptive et al. 2005 Trigeminal neuron-mediated InjectionRight eye (red) neurogenic inflammation (Evans blue)

Slide 19: Interim Data from NIH Phase 1 Study
•Interim Data 56 57 Lymphoma, pain 68 55 Low 61 Patient RTX NRS 19 6 yMTD 7.3 8.3 8.0 9.0 8.6 advanced (m) (f) Data Improved Demographics Study 49 Metastatic 21Bedridden 38.4 8/3/12 back not Clinically 54Wheelchair-bound 6Breakthrough cancer Baseline presented Date = 5/9/11 5/10/12 10/23/12 2/13/13

Slide 20: Next Steps for Intractable Cancer Pain
Next Under Intractable ~3 20 years Steps NIH Sorrento forcancer for CRADA clinical RTX IND pain Development development clinical Phase 1/2 trial (intrathecal injection); n~40 n~13 patients Filing Phase 1/2 for MUMS trial for designation osteosarcomafor(intraganglionic osteosarcoma ininjection); dogs

Slide 21: Immunotherapy and ADC Programs
Immunotherapy Mono- &ADC Proprietary 21 and + BiG-MAB Toxins Programs specific Antibodies

Slide 22: G-MAB: Proprietary Antibody Library
G-MAB: Proprietary RNA Freedom-To-Operate No Most G High Difficult Antibody Size 22Protein-Coupled stacking of Value amplification Difficult Target Targets: Library Drug technology: Oncology royalties Antigen Targets: Conjugates: ofReceptors used Therapeutic Fully High Targets: Very forsuccessful hu

Slide 23: Anti-PD-L1 Immune Modulation and Tumor Inhibition
Anti-PD-L1 Immune I(%) — Competitor Day *Sorrento FNxenograft 23 ** *** *** IL-Growth mAbs (%) Modulation* mAb p<0.05,mAb mAbs Inhibiti @Cell mean model0.05 Exhibit T onTumor tumor Tumor mg/mL using(pg/mL) Potent Mouse volumes H1975 (pg/mL) Activity areModel** human Activation significantly NSCLC ce

Slide 24: Potent Antibody Against Difficult GPCR Target
Potent 133.5 ** 24 Cell 14 Antibody Competitor e** 2.5 Untreated Disease Scor Binding Sorrento 1.5 After 15 16 17 18against mAb 2Sorrento 21 03 Experimental 0.5 *Days Disease0.17 mAb mAb 19 (EC50 Difficult 21 22–23 Induction 20against Auto-immune nM) C-CGPCR Target* 24Chemokine 25 26 27 28Receptor E

Slide 25: Key Antibody Drug Conjugate Components
Antibody Key 1. 2. 3. Drug 25 Target-specific Potent Linker Components: released cytotoxic and Drugconjugation inConjugates CANCER internalizing prodrugs chemistries (ADCs) CELL antibody

Slide 26: Proprietary High Potency Toxins
Proprietary (Breast SKBR3 Duostatins Duostatin DM1 26 (conventional; Cancer toxin vs. HighDM1 Cell 1 Potency (K-lock) Line) Duostatins NHS)Duostatin Duostatin MMAE vs. MMAE (conventional; Toxins toxin 1 (K-lock) maleimide) Duostatin toxin 2 (K-lock) >15x higher Duostatin toxin 2 (K-lock) potency

Slide 27: K-Lock Conjugation
K-Lock 2Current 27 2-8 industry 1 needConjugation Proprietary Sorrento’s purified 0No for: standard homogenous 1 2K-Lock Enables non-naturalchemistry Homogeneous chemistry ADCamino3 acids 0 ADCs genetic re-engineering enzymatic posttranslational modification

Slide 28: C-Lock Conjugation
C-Lockconjugation Current Maleimide Destabilizes Drug-antibody Sorrento’s C-lock Enhances 28 Conjugation industry ADC proprietary conjugation antibody linkage stability standard Stabilizes structure C-Lock not Prolongs stable chemistry ADCs Reduced Off-target PK profile target drug Reduced specifici

Slide 29: Fast Track to ADC IND
Proprietary Payload Fast Identification 29 trackpool toADC IND linkers of optimal Screening conjugation combination and Optimization 20 panel of linker, 50 panel Panels conjugation (up to) chemistry and drug payload essential for efficient and expedited development from target to candidates

Slide 30: Investment Highlights
Investment G-MAB RTX Cynviloq Late-Stage Product Addresses Abbreviated Intractable Ongoing Three Targeted Proprietary First Bi-specific 30 ADC therapeutic potential launch & Cancer Phase multi-billion in Cancer ADC antibodies Highlights linker/conjugation regulatory clinic expected drug 1/2 antibody

Slide 31: ARK: Developing Man's Best Friend Therapeutic Solutions
Developing Man’s Animal ARK A 31Subsidiary Life Health Companions Therapeutic of SorrentoSolutions to Help

Slide 32: Ark-001 in Osteosarcoma
Ark-001 in Osteosarcoma 32

Slide 33: Novel Products Targeting Unmet Needs in Animal Health
Novel (Pain Ark-001 Canine (Neuropathic Ark-002 Navicular (Idiopathic Ark-003 (Inflammation Ark-004 (Staph Ark-005 Ark-006 Ark-007 Potential Ark 33 001, assoc/ Products Infections Osteoarthritis) (Mastitis (Post in 002, Syndrome/Laminitis) Cystitis license wPain- 003 Surgical and Canine Potentially

Slide 34: Disease-Specific Small Animal Market Factors
Disease-Specific Small Disease/Drug Ark-001 Osteosarcoma/Pain Ark-005 Osteoarthritis/Pain Recurring Ark-003 Interstitial Unmet High Opiates Competition Alternative Amputation NSAIDs Antibiotics Anti-anxiety *83 4Prevalence **MRSA Level Unknown Transformative Moderate May TBD *APPA **Veterinary 34MMd

Slide 35: Disease-Specific Large Animal Market Factors
Disease-Specific Large Ark-006 Disease/Drug Ark-004 Ocular Ark-002 Unmet Laminitis Mastitis Antibiotics Competition Eye Antibacterial Pain Lidocaine Peripheral Approximately Prevalence High *9.2 Level Vaccine TBD: Moderate *Potentially ** 35Making 15% US drops M Killers No Animals of Horse Pain/Ocul

Slide 36: Animal Health Competitor Companies and Valuations
ARATANA KINDRED ARK Products None Disease >10 10 >15 Pain Time Near Market $529 $295 IPO 36 TBD Appetite Cancer Osteoarthritis Term M ANIMAL toValuation Area market on(KIN) in development (PETX) Market GI, Focus Stimulants HEALTH Allergy ofInfections Competitor Inflammation etc Interstitial Companie

Slide 37: Contact
CancerJiTherapeutics Next-Generation sorrento Henry Contact: President and CEO hji@sorrentotherapeutics.com (858) 668-6923
Source: SEC EDGAR · 8-K filed Jun 3, 2014
More decks from Sorrento Therapeutics, Inc.
Presentation (August 2023)9 slides · Aug 1, 2023
SPAC Merger (March 2022)21 slides · Mar 18, 2022
Technical Presentation (January 2022)13 slides · Jan 21, 2022
SPAC Merger (December 2021)57 slides · Dec 13, 2021
Technical Presentation (November 2021)9 slides · Nov 29, 2021
Investor Presentation (September 2021)37 slides · Sep 13, 2021